Peng is the founder of Novatio Ventures and an entrepreneurially minded investor with deal origination, financing, operations, legal, IP, and fund management expertise developed at leading firms. Prior to founding Novatio, Peng was Vice President, Business Development at DRI Capital, a leading life sciences private equity firm with more than US$3B of assets under management. Peng was responsible for biotech investment origination and acquisitions at DRI Capital and was a key contributor to the structuring and formation of Drug Royalty III, the firm’s US$1.45B third managed fund. Prior to joining DRI Capital, Peng was Director and Senior Counsel at Amgen and served as the general counsel and a member of the senior management team of the company’s Canadian affiliate. Previous to Amgen, Peng was Director of Legal Affairs at Teva, where he devised, implemented, and managed successful IP and regulatory strategies to realize first-to-market opportunities.
Peng began his career as an attorney at Gilbertʼs LLP, a biopharmaceutical focused boutique law firm, and then at Torys LLP, as a member of its life sciences and intellectual property practices. Peng holds an MSc in molecular biology and evolutionary ecology from the University of Toronto and a JD from Queenʼs University. He is fluent in Mandarin.